OmniAb (OABI) to Post Earnings on Thursday

Posted by on Aug 5th, 2026

OmniAb (NASDAQ:OABI – Get Free Report) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $4.6930 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

OmniAb (NASDAQ:OABI – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. The company had revenue of $14.43 million for the quarter, compared to the consensus estimate of $5.60 million. OmniAb had a negative net margin of 187.59% and a negative return on equity of 20.31%. On average, analysts expect OmniAb to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

OmniAb Stock Up 2.0%

Shares of OABI stock opened at $2.00 on Wednesday. OmniAb has a 12 month low of $1.30 and a 12 month high of $2.79. The company’s fifty day simple moving average is $2.28 and its 200-day simple moving average is $1.95. The firm has a market cap of $289.56 million, a PE ratio of -4.35 and a beta of 0.45.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OABI. AQR Capital Management LLC bought a new stake in shares of OmniAb during the 1st quarter worth approximately $25,000. Osaic Holdings Inc. grew its stake in shares of OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after buying an additional 9,716 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after buying an additional 10,438 shares in the last quarter. Cerity Partners LLC increased its holdings in OmniAb by 111.5% during the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after buying an additional 11,919 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in OmniAb during the fourth quarter worth $54,000. Institutional investors and hedge funds own 72.08% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Get Our Latest Analysis on OmniAb

About OmniAb

(Get Free Report)

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.

Read More

Earnings History for OmniAb (NASDAQ:OABI)

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.